TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01178008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Description: Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
Study: NCT03664440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nevirapine
Description: Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine
Description: Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
Study: NCT04278027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: CIRCuiTS is a web-based computerised CR therapy, delivered by a therapist but supplemented with independent sessions to facilitate massed practice. It targets metacognition, particularly strategy use, in addition to providing massed practice of basic cognitive functions. The therapist facilitates motivation, metacognitive and strategy development and generalisation of learning by encouraging the participant to learn about and regulate their cognitive performance and to transfer this learning to meet real-world goals. Therapists provide additional scaffolding for CR tasks to ensure consistent successful performance. Independent sessions involve carrying out cognitive tasks allocated by the therapist to ensure scaffolded learning (Reeder et al.2017)
Study: NCT01987895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid 250 mg as oral suspension twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 125 mg as oral capsules 4 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cadazolid-matching placebo
Description: Placebo matching cadazolid and administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin-matching placebo
Description: Placebo capsules matching vancomycin and administered orally 4 times per day
Study: NCT05108753

Intervention type: OTHER
Intervention: Procedure/Surgery
Description: Transanal Total Mesorectal Excision

Intervention type: OTHER
Intervention: Procedure/Surgery
Description: Transanal Total Mesorectal Excision

Intervention type: OTHER
Intervention: Procedure/Surgery
Description: Transanal Total Mesorectal Excision
Study: NCT02974400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based, CBT-oriented, guided self-help
Description: The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
Study: NCT02947100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCD-Omegatex™
Description: Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose.
Study: NCT01336049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 200mg/week
Study: NCT01907867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
Study: NCT01789801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RAP palpation only
Description: Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RAP with ultrasound guidance
Description: Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
Study: NCT01883661

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BMMNC
Description: Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
Study: NCT01557868

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hylan G-F 20
Description: Three 2 cc injections at weekly intervals

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1% sodium hyaluronate
Description: Three 2 cc injections at weekly intervals
Study: NCT04288427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Patients who are candidates to receive 5ARI therapy, Finasteride, for clinical medical management of lower urinary tract symptoms will begin treatment once deemed eligible. They will be assess every 6 months for changes in urinary symptom scores and their responsiveness to the Finasteride treatment will be assessed at the 12-month time point. MRIs of prostate taken at the start of study and at the 3 year time point will assess prostate size and changes in size as well as degree of inflammatory changes. Gene expression of SRD5A2 as well as methylation pattern will be tested on prostate tissue samples, where hormonal androgen/estrogen levels will also be assessed as they are in blood samples.
Study: NCT01593449

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based social networking intervention
Description: Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based social networking intervention
Description: Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
Study: NCT02383303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Development Account and financial education
Description: The Program intervention includes a matched savings account (Individual Development Account) and financial education.
Study: NCT01998347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Study: NCT01315288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One of 6 video presentation by one of 4 presenters

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One of 6 video presentation by one of 4 presenters

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One of 6 video presentation by one of 4 presenters

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One of 6 video presentation by one of 4 presenters

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One of 6 video presentation by one of 4 presenters
Study: NCT04525040

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProbioKid®
Description: Probiokid formulation includes three probiotic strains and fructooligosaccharides.

Intervention type: OTHER
Group type: OTHER
Intervention: Pragmatic comparator
Description: Standard of care as usual without a preventive intervention
Study: NCT02969083

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNU
Description: Radical surgical removal by open or laparoscopic access

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNU
Description: Radical surgical removal by open or laparoscopic access

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNU
Description: Radical surgical removal by open or laparoscopic access

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNU
Description: Radical surgical removal by open or laparoscopic access

Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNU
Description: Radical surgical removal by open or laparoscopic access

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1

Intervention type: DRUG
Group type: OTHER
Intervention: M-VAC Protocol
Description: Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2

Intervention type: DRUG
Group type: OTHER
Intervention: M-VAC Protocol
Description: Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
Study: NCT03932916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Pamoate for Injection 17mg
Description: A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Pamoate for Injection 34mg
Description: A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride 5mg
Description: A tablet of 5mg Donepezil Hydrochloride will be administered once.
Study: NCT03145103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT ASPHINA 409
Description: intraocular lens
Study: NCT03648138

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sugary drink warning labels
Description: This information appears in the description of the study arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugary drink warning labels
Description: This information appears in the description of the study arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugary drink warning labels
Description: This information appears in the description of the study arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugary drink warning labels
Description: This information appears in the description of the study arms.
Study: NCT01907867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
Study: NCT03511690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRCA-Gist
Description: BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRCA-Gist
Description: BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing.
Study: NCT02993523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Solution for subcutaneous or intravenous administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Solution for subcutaneous or intravenous administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Solution for subcutaneous or intravenous administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Tablet
Study: NCT05495529

Intervention type: PROCEDURE
Intervention: Thermal Ablation
Description: Data collection about complications, succes of the procedure, succes of complete treatement, recurrence, biologic pertubations.
Study: NCT04261647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-taping techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.
Study: NCT00683761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-TM601
Description: In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
Study: NCT03634527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure
Description: Light touch using vaccaria seeds on specific points of the ear
Study: NCT02993523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT02954978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: 25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
Study: NCT03634527

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Auricular Point Acupressure-
Description: Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
Study: NCT02447770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mars Cocoa Extract Capsules
Description: Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
Study: NCT01908309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iobitridol 350
Study: NCT02954978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 150mg oral capsule [Tasigna]
Description: 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 300mg oral capsule [Tasigna]
Description: 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
Study: NCT03952078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-818
Description: Interleukin-2 inducible T-cell Kinase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-818
Description: Interleukin-2 inducible T-cell Kinase Inhibitor
Study: NCT01908309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol 320
Study: NCT01031628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: 400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: 400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: 400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
Study: NCT00801463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tripterygium wilfordii (TW)
Description: Pre 30mg/d +TW 120 mg/d, po for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tripterygium wilfordii (TW)
Description: Pre 30mg/d +TW 120 mg/d, po for 12 weeks
Study: NCT04229810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STD-02
Description: Conventional standardized ventilatory approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iOLA-iHFNC
Description: Indivudualized perioperative open lung ventilatory approach.
Study: NCT02281123

Intervention type: OTHER
Intervention: SF36 (QQoL)
Description: use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
Study: NCT00940745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Aspiration and Thrombolysis
Description: Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
Study: NCT03552601

Intervention type: OTHER
Group type: OTHER
Intervention: traditional speed
Description: ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1000mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.

Intervention type: OTHER
Group type: OTHER
Intervention: faster speed
Description: ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1500mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
Study: NCT00940745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
Study: NCT04155970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy, which includes spinal manipulation; spinal mobilisation; light massage; and trigger point therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-informed home management booklet
Description: The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-informed home management booklet
Description: The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.
Study: NCT02145845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injectable SIS
Description: Injectable SIS
Study: NCT02522728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CR
Description: Implantation of Knee Prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon PS
Description: Implantation of Knee Prosthesis
Study: NCT01099917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maitake
Description: Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test.